Evidence map›Paper›PMID 34334119›Full record

ArticleCell cycle (Georgetown, Tex.)2021

Inhibition of LOXL1-AS1 alleviates oxidative low-density lipoprotein induced angiogenesis via downregulation of miR-590-5p mediated KLF6/VEGF signaling pathway.

Xuan Cheng, Zhiwei Liu, Haifeng Zhang, Yajun Lian

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Xuan ChengDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou Henan, China.
Zhiwei LiuDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou Henan, China.
Haifeng ZhangDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou Henan, China.
Yajun LianDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou Henan, China.
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidences have confirmed that long non-coding RNA LOXL1-AS1 functions in multiple human diseases. Here, we aim to explore the function and mechanism of LOXL1-AS1 in modulating oxidized low-density lipoprotein (ox-LDL)-induced angiogenesis of endothelial cells (ECs). Presently, we found that LOXL1-AS1 and KLF6 were upregulated in ECs treated by Ox-LDL in a dose- and time-dependent manner while miR-590-5p was downregulated. Overexpression of LOXL1-AS1 aggravated Ox-LDL mediated ECs proliferation and migration, and promoted angiogenesis both

Indexed as

MicroRNAsRNA, Long NoncodingAmino Acid OxidoreductasesApoptosisCell ProliferationDown-RegulationEndothelial CellsHumansKruppel-Like Factor 6Lipoproteins, LDLOxidative StressPhosphatidylinositol 3-KinasesSignal TransductionVascular Endothelial Growth Factor AAmino Acid OxidoreductasesKLF6 protein, humanKruppel-Like Factor 6Lipoproteins, LDLLOXL1 protein, humanMicroRNAsMIRN590 microRNA, humanPhosphatidylinositol 3-KinasesRNA, Long NoncodingVascular Endothelial Growth Factor AAtherosclerosisendothelial cellklf6loxl1-as1miR-590-5pvegf signaling pathway

Identifiers

PMID34334119
PMCPMC8489901
OpenAlexW3189241106

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.